Dawnrays Pharmaceutical (Holdings) Limited Stock price

Equities

2348

KYG2687M1006

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:03 2024-03-28 am EDT 5-day change 1st Jan Change
1.17 HKD -2.50% Intraday chart for Dawnrays Pharmaceutical (Holdings) Limited -11.36% +11.43%

Financials

Sales 2021 1.17B 161M 1.26B Sales 2022 1.28B 177M 1.38B Capitalization 1.76B 244M 1.91B
Net income 2021 358M 49.53M 388M Net income 2022 358M 49.53M 388M EV / Sales 2021 1.06 x
Net cash position 2021 807M 112M 873M Net cash position 2022 1.07B 148M 1.16B EV / Sales 2022 0.54 x
P/E ratio 2021
5.73 x
P/E ratio 2022
4.93 x
Employees 1,143
Yield 2021
4.79%
Yield 2022
6.63%
Free-Float 39.99%
More Fundamentals * Assessed data
Dynamic Chart
Dawnrays Pharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 12 June 2024 CI
Dawnrays' 2023 Profit Falls 9% on Lower Revenue MT
Dawnrays Pharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Akeso Unit Buys 35% Stake in Biopharmaceutical Firm from Dawnrays; Akeso Shares Slide 3% MT
Dawnrays Pharmaceutical Limited Declares Interim Dividend for the Year Ending December 31, 2023, Payable on October 5, 2023 CI
Dawnrays Pharmaceutical Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Dawnrays Pharmaceutical Limited Announces the National Medical Products Administration Accepts the New Drug Application for Ebronucimab Injection CI
Dawnrays Pharmaceutical Limited Approves Final Dividend for the Year Ended 31 December 2022 CI
Dawnrays Pharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2022, Payable on 13 June 2023 CI
Dawnrays Pharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Dawnrays Pharmaceutical Unit to Provide $14.4 Million Loan to AD Pharmaceuticals MT
Dawnrays Pharmaceutical Limited(SEHK:2348) dropped from S&P Global BMI Index CI
Dawnrays Pharmaceutical Limited Announces Interim Semi-Annual Ordinary Dividend for the Six Months Ended 30 June 2022, Payable on 05 October 2022 CI
Dawnrays Pharmaceutical Limited Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Dawnrays Pharmaceutical Limited Declares Final Dividend for the Year Ended December 31, 2021 CI
More news
1 day-2.50%
1 week-11.36%
Current month-0.85%
1 month-1.68%
3 months+13.59%
6 months+4.46%
Current year+11.43%
More quotes
1 week
1.10
Extreme 1.1
1.35
1 month
1.10
Extreme 1.1
1.35
Current year
1.03
Extreme 1.03
1.35
1 year
0.98
Extreme 0.98
1.40
3 years
0.98
Extreme 0.98
1.93
5 years
0.84
Extreme 0.84
1.93
10 years
0.84
Extreme 0.84
4.07
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 22-02-15
Director of Finance/CFO 59 02-11-30
Chairman 75 02-09-30
Members of the board TitleAgeSince
Chairman 75 02-09-30
Director/Board Member 79 02-09-30
Director/Board Member 49 05-10-31
More insiders
Date Price Change Volume
24-03-28 1.17 -2.50% 740 000
24-03-27 1.2 +2.56% 388,000
24-03-26 1.17 -0.85% 474,000
24-03-25 1.18 -10.61% 2,790,000
24-03-22 1.32 0.00% 434,000

Delayed Quote Hong Kong S.E., March 28, 2024 at 04:08 am EDT

More quotes
Dawnrays Pharmaceutical (Holdings) Limited is an investment holding company principally engaged in the development, manufacture and sale of non-patented pharmaceutical medicines. The products include intermediate pharmaceutical, bulk medicines and finished drugs. The Company operates its business through two segments. The Intermediates and Bulk Medicines segment is engaged in the manufacture and sale of intermediates and bulk medicines. The Finished Drugs segment is engaged in the manufacture and sale of finished drugs, including antibiotics finished drugs and non-antibiotics finished drugs.
More about the company
  1. Stock
  2. Equities
  3. Stock Dawnrays Pharmaceutical (Holdings) Limited - Hong Kong S.E.